Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable

Inclusion Criteria:

- The patient has given informed consent

- The patient is willing and able to abide by the protocol

- The patient has cancer and curative therapy is unavailable or standard therapy has
failed

- The patient is at least 18 years of age

- The patient has adequate ability to perform activities of daily living

- The patient has recovered from significant toxicities of previous therapy

- The patient has adequate organ function as assessed by laboratory testing

Exclusion Criteria:

- The patient has had prior treatment with high-dose chemotherapy requiring stem cell
rescue

- The patient is currently on treatment on another therapeutic clinical trial or has
received an investigational drug within 4 weeks prior to first dose on this study

- The patient has had prior surgery, radiation or systemic therapy within 4 weeks of
starting the study

- The patient has a history of CNS cancer

- The patient has an unstable medical condition including (not limited to) cardiac
disease, HIV/AIDS, history of stroke, hepatitis or significant paricardial, pleural
or peritoneal effusion

- The patient is pregnant or breastfeeding